BioWorld MedTech

Sep. 7, 2016

View Archived Issues

Danaher to buy Cepheid for $4B with an eye on diagnostics growth runway

Washington-based Danaher Corp. (NYSE: DHR) determined that buying molecular diagnostics company Cepheid Inc. (NASDAQ: CPHD) will boost its position in the molecular diagnostics space, but Danaher's investors may take more convincing. Read More

CFDA proposes priority review pathway for new medical devices

Read More

SSRI effects are too much of a good thing for bones

Read More

Telehealth app Mydoc aims to ease medical cost strains in Singapore

Read More

Appointments and advancements

Read More

Financings

Read More

Daily M&A

Read More

Other news to note

Read More

MDD's Oncology Extra

Read More